ProCE Banner Activity

Ivosidenib or Enasidenib Plus Standard Induction and Consolidation Chemotherapy in Newly Diagnosed, IDH1/IDH2-Mutated AML

Slideset Download
Conference Coverage
In patients with newly diagnosed AML with IDH1 or IDH2 mutations, addition of ivosidenib or enasidenib to standard chemotherapy was associated with good tolerability, mutation clearance, and MRD negativity.

Released: December 18, 2018

Expiration: December 17, 2019

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology